IIM
CRVS icon

INTECH Investment Management’s Corvus Pharmaceuticals CRVS Stock Holding History

INTECH Investment Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$211K Sell
14,121
-9,260
-40% -$129K ﹤0.01% 1771
2026
Q1 		$342K Sell
23,381
-12,592
-35% -$201K ﹤0.01% 1511
2025
Q4 		$277K Buy
35,973
+9,812
+38% +$77.4K ﹤0.01% 1800
2025
Q3 		$193K Buy
26,161
+383
+1% +$1.96K ﹤0.01% 2084
2025
Q2 		$103K Buy
+25,778
New +$93.8K ﹤0.01% 2284

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

INTECH Investment Management's CRVS Position: Q2 2026 in Review

INTECH Investment Management reduced its Corvus Pharmaceuticals (CRVS) stake by 40% in Q2 2026, selling an estimated $129K and leaving 14,121 shares worth $211K. The position accounts for ﹤0.01% of the portfolio, ranked #1771.

INTECH Investment Management first reported a position in CRVS in Q2 2025 and has held it in 5 quarters since. The position peaked at $342K in Q1 2026. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • INTECH Investment Management held 14,121 shares of Corvus Pharmaceuticals worth $211K as of Q2 2026.
  • INTECH Investment Management sold 9,260 Corvus Pharmaceuticals shares in Q2 2026, an estimated $129K.
  • Corvus Pharmaceuticals made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1771 holding.
  • INTECH Investment Management first reported a position in Corvus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • INTECH Investment Management's Corvus Pharmaceuticals position peaked at $342K in Q1 2026.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.